Quarterly report pursuant to Section 13 or 15(d)

Development Awards (Details Narrative)

v3.5.0.2
Development Awards (Details Narrative)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 20, 2015
USD ($)
Installments
May 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Jun. 30, 2016
USD ($)
Development Award [Line Items]        
Deferred revenue   $ 1,250,000    
Cystic Fibrosis Foundation Therapeutics Inc [Member]        
Development Award [Line Items]        
Amount received upon execution of award agreement     $ 1,250,000  
Cystic Fibrosis Foundation Therapeutics Inc [Member] | August 2016 [Member]        
Development Award [Line Items]        
Amount received upon execution of award agreement       $ 1,000,000
Resunab [Member]        
Development Award [Line Items]        
Number of installments | Installments 3      
Percentage of royalty over receivables under agreement 500.00%      
Payment due period after the first commercial sale 90 days      
Royalty payment, sales target $ 500,000,000      
Resunab [Member] | Upon Transfer Sale Or Licensing [Member]        
Development Award [Line Items]        
Royalty payable 15,000,000      
Resunab [Member] | Cystic Fibrosis Foundation Therapeutics Inc [Member]        
Development Award [Line Items]        
Amount received upon execution of award agreement   $ 1,250,000 1,250,000  
Deferred revenue     $ 2,500,000  
Remaining amount receivable upon achievement of certain milestones       $ 1,500,000
Maximum [Member] | Resunab [Member]        
Development Award [Line Items]        
Development award received 5,000,000      
Maximum [Member] | Resunab [Member] | Upon Commercialization Of The Product [Member]        
Development Award [Line Items]        
Royalty payable 25,000,000      
Maximum [Member] | Resunab [Member] | Upon Reaching The Sales Target [Member]        
Development Award [Line Items]        
Royalty payable $ 5,000,000